Kezar Life Sciences stock (US49374L1008): Merger with Aurinia completes, shares cancelled

Kezar Life Sciences has completed its merger with Aurinia Pharma U.S., resulting in the cancellation of all outstanding shares on May 11, 2026. Tang Capital reports zero ownership in latest SEC filing.

Kezar Life Sciences completed its merger with Aurinia Pharma U.S., Inc. on May 11, 2026, leading to the cancellation of all issued and outstanding common shares. The company now operates as a wholly owned subsidiary of Aurinia. This development was confirmed in an amended Schedule 13D filing by Tang Capital Management and Kevin Tang, who reported beneficial ownership of 0 shares, or 0% of the class, as of that date, according to StockTitan as of May 14, 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Kezar Life Sciences
• Sector/industry: Pharmaceuticals/Biotech
• Headquarters/country: United States
• Core markets: Immunology, autoimmune diseases
• Key revenue drivers: Clinical-stage drug candidates
• Home exchange/listing venue: Nasdaq (KZR)
• Trading currency: USD

Kezar Life Sciences: core business model

Kezar Life Sciences focused on developing novel treatments for autoimmune and inflammatory diseases through selective immunoproteasome inhibition. Its lead candidate, zetomipzomib, targeted conditions like lupus nephritis and autoimmune hepatitis. The company operated as a clinical-stage biopharmaceutical firm, advancing therapies from discovery through mid-stage trials prior to the merger.

Main revenue and product drivers for Kezar Life Sciences

Pre-merger, Kezar derived value from its pipeline, particularly zetomipzomib, which showed promise in Phase 2b trials for lupus nephritis as reported in prior SEC filings. The company had no approved products generating revenue, relying on funding from equity offerings and partnerships. Post-merger integration with Aurinia expands access to immunology expertise and resources.

Why Kezar Life Sciences matters for US investors

Listed on Nasdaq, Kezar provided US investors exposure to biotech innovation in immunology. The merger with Aurinia, a player in autoimmune therapies, integrates Kezar's assets into a broader platform, potentially enhancing development for US-listed biotech portfolios amid rising demand for kidney disease treatments.

Conclusion

The completion of the merger marks a transformative event for Kezar Life Sciences, shifting it to wholly owned status under Aurinia with all shares cancelled. Tang Capital's exit underscores the deal's finality. Investors should monitor Aurinia's updates for pipeline progress and integration details.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.